Matthew Burge

5.5k total citations
123 papers, 1.1k citations indexed

About

Matthew Burge is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Matthew Burge has authored 123 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 106 papers in Oncology, 36 papers in Pulmonary and Respiratory Medicine and 32 papers in Pathology and Forensic Medicine. Recurrent topics in Matthew Burge's work include Colorectal Cancer Treatments and Studies (55 papers), Genetic factors in colorectal cancer (32 papers) and Cancer Genomics and Diagnostics (26 papers). Matthew Burge is often cited by papers focused on Colorectal Cancer Treatments and Studies (55 papers), Genetic factors in colorectal cancer (32 papers) and Cancer Genomics and Diagnostics (26 papers). Matthew Burge collaborates with scholars based in Australia, United States and Canada. Matthew Burge's co-authors include Vicki Whitehall, Timothy Price, David Wyld, Peter Gibbs, Jeremy Shapiro, Christos S. Karapetis, Niall C. Tebbutt, Nick Pavlakis, Eric Van Cutsem and Eva Segelov and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Matthew Burge

115 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matthew Burge Australia	19	703	234	224	218	215	123	1.1k
Catherine Shannon Australia	20	704 1.0×	183 0.8×	286 1.3×	148 0.7×	285 1.3×	48	1.2k
David Watkins United Kingdom	22	747 1.1×	201 0.9×	446 2.0×	322 1.5×	254 1.2×	81	1.4k
Martha Donoghue United States	16	696 1.0×	163 0.7×	400 1.8×	247 1.1×	285 1.3×	27	1.2k
Sandra J. Casak United States	18	455 0.6×	148 0.6×	215 1.0×	171 0.8×	107 0.5×	32	1.0k
Kimberly Perez United States	16	701 1.0×	398 1.7×	103 0.5×	135 0.6×	180 0.8×	70	1.1k
Thomas J. Semrad United States	15	395 0.6×	99 0.4×	237 1.1×	257 1.2×	162 0.8×	51	890
George Zarkavelis Greece	15	458 0.7×	157 0.7×	170 0.8×	169 0.8×	158 0.7×	52	813
Desirée Hao Canada	23	842 1.2×	128 0.5×	633 2.8×	469 2.2×	201 0.9×	90	1.5k
Morena Fasano Italy	20	680 1.0×	132 0.6×	535 2.4×	605 2.8×	244 1.1×	63	1.4k
Prabhat Singh Malik India	17	493 0.7×	101 0.4×	416 1.9×	379 1.7×	236 1.1×	116	1.1k

Countries citing papers authored by Matthew Burge

Since Specialization

Citations

This map shows the geographic impact of Matthew Burge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Burge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Burge more than expected).

Fields of papers citing papers by Matthew Burge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Burge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Burge. The network helps show where Matthew Burge may publish in the future.

Co-authorship network of co-authors of Matthew Burge

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Burge. A scholar is included among the top collaborators of Matthew Burge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Burge. Matthew Burge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pattison, David A., Grace Kong, Timothy Akhurst, et al.. (2025). Peptide receptor radionuclide therapy in malignant insulinoma. Endocrine Related Cancer. 32(6).

Takashima, Atsuo, Pilar García‐Alfonso, Ali Ayberk Beşen, et al.. (2024). Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study. European Journal of Cancer. 205. 114036–114036. 7 indexed citations

Roy, Amitesh, Tim Bright, Nimit Singhal, et al.. (2024). Neoadjuvant immuno-chemo-radiotherapy in operable esophageal and gastroesophageal junction adenocarcinoma with carboplatin, paclitaxel plus radiotherapy and avelumab (anti-PDL1 antibody): Neo-CREATE trial.. Journal of Clinical Oncology. 42(16_suppl). 4086–4086. 1 indexed citations

Ramsay, Robert G., Catherine Mitchell, Shienny Sampurno, et al.. (2024). A non-randomised open-label exploratory ‘window of opportunity’ study of TG02 treatment in patients with locally advanced primary and recurrent RAS mutant colorectal cancer. Heliyon. 11(1). e41364–e41364. 2 indexed citations

Méndez, Guillermo, Joseph Chao, Radim Němeček, et al.. (2024). First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study. Journal of Clinical Oncology. 42(17). 2080–2093. 27 indexed citations

Yang, Tsai‐Sheng, Hong‐Hwa Chen, Tae Won Kim, et al.. (2023). Prospective, open‐label, and observational study of cetuximab for metastatic colorectal carcinoma: The OPTIM1SE study. Asia-Pacific Journal of Clinical Oncology. 19(6). 672–680.

Pattison, David A., J. Younger, Avinash Chikatamarla, et al.. (2023). Cardiac metastases from neuroendocrine neoplasms: complementary role of SSTR PET/CT and cardiac MRI. Journal of Nuclear Cardiology. 30(6). 2676–2691. 2 indexed citations

Le, Dung T., Luis A. Díaz, Tae Won Kim, et al.. (2023). Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164. European Journal of Cancer. 186. 185–195. 46 indexed citations

Tacey, Mark, Benjamin Thomson, Michael Michael, et al.. (2022). Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry. European Journal of Cancer. 174. 102–112. 19 indexed citations

10.

Wong, Vanessa, Jeremy Shapiro, Rachel Wong, et al.. (2021). Treatment and Outcomes of Oligometastatic Colorectal Cancer Limited to Lymph Node Metastases. Clinical Colorectal Cancer. 20(4). e233–e239. 4 indexed citations

11.

Gan, Hui, Matthew Burge, Benjamin Solomon, et al.. (2021). A Phase 1 and Biodistribution Study of ABT-806i, an ¹¹¹In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806. Journal of Nuclear Medicine. 62(6). 787–794. 15 indexed citations

12.

Degeling, Koen, Hui‐Li Wong, Hendrik Koffijberg, et al.. (2020). Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data. PharmacoEconomics. 38(11). 1263–1275. 3 indexed citations

13.

Ladwa, Rahul, David A. Pattison, Matthew Burge, et al.. (2018). Positron Emission Tomography (PET) predictors of tumor response to Peptide Receptor Radionuclide Therapy (PRRT) in metastatic Neuroendocrine Tumors (NET). Neuroendocrinology. 106. 249–249. 1 indexed citations

14.

Plage, Stefanie, Alexandra Gibson, Matthew Burge, & David Wyld. (2017). Cancer on the margins: experiences of living with neuroendocrine tumours. Health Sociology Review. 27(2). 153–167. 10 indexed citations

15.

Gan, Hui, Matthew Burge, Benjamin Solomon, et al.. (2017). A Phase 1 and Biodistribution Study of Abt-806I, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-Egfr Antibody Abt-806. Internal Medicine Journal. 47. 13–13. 2 indexed citations

16.

Ladwa, Rahul, Matthew Burge, & David Wyld. (2016). A Single Centres Experience of Cardiac Metastasis from Neuroendocrine Tumours (NET). Queensland's institutional digital repository (The University of Queensland). 1 indexed citations

17.

Burge, Matthew, et al.. (2014). Cetuximab Use in Metastatic Colorectal Cancer At Five Large Queensland Public Hospitals: Comparison to Key Clinical Trials. Queensland's institutional digital repository (The University of Queensland). 1 indexed citations

18.

Burge, Matthew, et al.. (2014). Time from diagnosis of rectal adenocarcinoma to commencement of long course chemoradiotherapy (Lccrt) for metropolitan versus rural patients referred to a Queensland tertiary referral hospital. Queensland's institutional digital repository (The University of Queensland). 1 indexed citations

19.

Chan, Bryan, et al.. (2014). Rural Oncology Care Via Teleoncology and Outreach Clinics: Patient and Staff Perspectives and Comparisons. Queensland's institutional digital repository (The University of Queensland). 1 indexed citations

20.

Wyld, David, et al.. (2012). Pulmonary Embolism in Medical Oncology Patients: Symptomatic Versus Incidental. Asia-Pacific Journal of Clinical Oncology. 8. 57–58. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact